# Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

> **NCT02265679** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 45 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** BIIL 284 BS, low dose, pediatric patients
- **DRUG:** BIIL 284 BS, medium dose, pediatric patients
- **DRUG:** BIIL 284 BS, high dose, pediatric patients
- **DRUG:** BIIL 284 BS, low dose, adult patients
- **DRUG:** BIIL 284 BS, medium dose, adult patients
- **DRUG:** BIIL 284 BS, high dose, adult patients
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02265679
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-10
- **Primary completion:** 2002-07
- **Final completion:** —
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2014-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02265679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02265679, "Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02265679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*